Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.

MP 7.01.40 Laser Treatment of Port Wine Stains

Medical Policy    
Original Policy Date
Last Review Status/Date
Reviewed with literature search/6:2014
  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.


Port wine stains are common vascular malformations that start as pink macules and, if untreated, tend to become darker and thicker over time. They usually occur on the face and neck, but can be located elsewhere on the body. Treatment with lasers (including pulsed dye lasers [PDL], Alexandrite, Nd:YAG lasers, and intense pulsed light [IPL]) is proposed.


Port wine stains are the most common of the vascular malformations, affecting approximately 3 in 1000 children. They are composed of networks of ectatic vessels and primarily involve the papillary dermis. Unlike many other birthmarks, port wine stains do not resolve spontaneously. In contrast, they typically begin as pink macules and become redder and thicker over time due to decreased sympathetic innervation. The depth of the skin lesions ranges from about 1 to 5 mm. Port wine stains are generally located on the face and neck but can occur in other locations such as the trunk or limbs.

Before the availability of laser treatment in the 1980s, there were no effective therapies for port wine stains. A laser is a highly focused beam of light that is converted to heat when absorbed by pigmented skin lesions. Several types of lasers have been used to treat port wine stains. Currently, the most common in clinical practice is the PDL, which uses yellow light wavelengths (585-600 nm) that selectively target both oxyhemoglobin and deoxyhemoglobin. PDLs penetrate up to 2 mm in the skin. Newborns and young children, who have thinner skin, tend to respond well to this type of laser; the response in thicker and darker lesions may be lower. Other types of lasers with greater tissue penetration and weaker hemoglobin absorption are used for hypertrophic and resistant port wine stains. In particular, alternatives to the PDL are the long-pulsed 1064 nm Nd:YAG and 755 nm pulsed Alexandrite lasers. The 1064 nm Nd:YAG laser requires a substantial degree of skill to use to avoid scarring. Carbon dioxide and argon lasers are relatively nonselective; they were some of the first lasers used to treat port wine stains but were associated with an increased incidence of scarring and are not currently used frequently in clinical practice to treat port wine stains. IPL devices emit polychromatic high-intensity pulsed light. Pulse duration is in the millisecond range, and devices use an emission spectrum ranging from 500 to 1400 nm. Compared with other types of lasers, IPL devices include both the oxyhemoglobin selective wavelengths emitted by PDL systems and longer wavelengths that allow deeper penetration into the dermis.

Regulatory Status

Several laser systems have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for a variety of dermatologic indications, including treatment of port wine stains. Approved lasers for this indication include the Candela® PDL system (Candela Corp., Wayland, MA), the Cynosure Photogenica® PDL (Cynosure Inc., Westford, MA), and the Cynosure Nd:YAG laser system. In addition, the Cynergy™ Multiplex Laser (Cynosure), a combined Nd:YAG and PDL was approved by FDA in 2005 for treatment of benign vascular and vascular dependent lesions, including port wine stains.

In 2003, the Lumenis® family of IPL systems was approved by FDA; indications for use include dermatologic applications. Subsequently, the NannoLight® IPL system (Global USA Distribution) was approved by FDA in 2008 and the Mediflash3 and Esterflash3 systems (Dermeo) were approved in 2010 for indications specifically including treatment of port wine stains.


Laser treatment of port wine stains in the presence of functional impairment related to the port wine stains may be considered medically necessary. (See Benefit Application section regarding reconstructive services.)

Treatment of port wine stains with lasers in combination with photodynamic therapy or topical angiogenesis inhibitors is considered investigational.

Policy Guidelines

Performance of a prior spot test is necessary to select suitable candidates for treatment and to determine the degree of scarring that may occur.

The size of the lesion may require more than one treatment.

Benefit Application
BlueCard/National Account Issues

State or federal mandates (e.g., FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.

The approach to laser treatment of port wine stains will depend on benefit language related to definitions of medically necessary, reconstructive, and cosmetic services. Procedures are considered reconstructive when intended to address a significant variation from normal related to accidental injury, disease, trauma, treatment of a disease or congenital defect. Not all benefit contracts include benefits for reconstructive services. Benefit language supersedes this document.


The policy was created in 1996 and was on “no further review” status from 2003 to 2010, at which time it returned to active review and was updated with a search of the MEDLINE database. Most recently, the literature was reviewed through May 5, 2014. Following is a summary of the key literature to date on laser treatment of port wine stains.

Laser treatment monotherapy

In 2011, a Cochrane review of trials on light or laser sources for treating port wine stains was published by Faurschou et al.(1) The review included randomized controlled trials (RCTs) comparing any laser or light source with any comparison intervention. Five RCTs with a total of 103 participants met inclusion criteria. The investigators reported that interventions and outcomes were too heterogenous for a meta-analysis of study findings. All studies used a within-participant (eg, split-side) design, and none included a sham treatment or no treatment group. Interventions in all of the trials were between 1 and 3 treatment sessions and all trials followed patients for less than 6 months’ follow-up. A primary efficacy outcome of the review was reduction in redness; investigators judged that a reduction of more than 20% would represent a clinically relevant effect. In all of the 5 trials, treatment with the pulsed dye laser (PDL) resulted in more than 25% reduction in redness in 50% to 100% of participants, depending on setting of the laser device. In addition, intense pulsed light (IPL) and the Nd:YAG laser also led to a reduction in redness in 1 trial each. The trials found that long-term adverse effects of laser and light treatment were rare; only 1 participant in 1 trial experienced scarring of the skin, and this person had a too-high dose of the Nd:YAG laser. The authors concluded that the evidence supports the use of the PDL as the treatment of choice for port-wine stains

Representative RCTs included in the Cochrane review and published more recently that evaluated laser treatment of port wine stains are described next.

In 2009, Faurschou et al in Denmark published a study with 20 patients with port wine stains.(2) Port wine stains were on the face (n=15), trunk (n=4), or extremities (n=1). Eight (40%) had previously untreated lesions, and the remainder were previously treated, but with types of lasers not under investigation in the study. Patients received 1 treatment with a PDL on a randomly selected side of the lesion (left/lower or right/upper) and IPL treatment on the other side. Blinded assessment 12 weeks’ posttreatment found a median of 65% percentage lightening on the PDL side and 30% on the IPL side (p<0.001). Fifteen (75%) of 20 patients had more than 70% lightening with PDL treatment compared with 6 (30%) in the IPL group; this difference was also statistically significant (p=0.014).

A 2010 study in Germany by Babilas et al was a split-face comparison of PDL and IPL treatment in 25 patients; 11 (40%) had previously untreated port wine stains, and the other 14 had received previous laser treatment.(3) Port wine stains were located in the face and neck region in 18 patients, the trunk in 3 patients, and the extremities in 4 patients. The previously untreated patients were treated with IPL, short-PDL (585 nm and 0.45-ms pulse duration), and long-PDL (584-600 nm and 1.5-ms pulse duration). Patients who previously failed either short- or long-PDLs did not receive that type of treatment. Blinded outcome assessment was done 6 weeks after treatment. In the treatment-naive group, assessors rated lightening as excellent (at least 75%) or good (51% to 75%) in at least 1 test spot in 7 of 11 (64%) patients after IPL treatment, 5 of 11 (45%) after long-PDL, and 1 of 11 (9%) after short-PDL (between group p value not reported). In the group that had been previously treated, lightening was rated as excellent or good in at least 1 test spot in 4 of 14 (29%) patients after IPL treatment, 1 of 14 (7%) after long-PDL treatment, and 0 (0%) after short-PDL treatment.

In 2012, Klein et al in Germany published findings of an RCT evaluating treatment with a diode laser augmented by the dye indocyanine green.(4) The study included 31 patients with port wine stains. Two areas of 2´2 cm were selected in each patient’s port wine stain. The areas were randomly assigned to receive treatment with a PDL or with an indocyanine green-augmented diode laser (ICG + DL). The cosmetic appearance of the lesions was assessed using a 5-point Likert-type scale (0=no clearance to 4=excellent clearance). Three months after treatment, the mean investigator-rated clearance score (SD) was 0.89 (0.99) for lesions receiving PDL treatment and 1.30 (1.29) for lesions receiving ICG + DL treatment. The difference in scores between groups was not statistically significant, p=0.11. At 3 months, patients rated the clearance level as a mean (SD) of 0.89 (0.88) after PDL treatment and 1.71 (1.24) after ICG + DL (p=0.004). Two patients in the diode laser treatment group experienced adverse events. There was 1 case of site-specific pain during ICG + DL treatment (8 on a 10-point scale) and 1 case of an atrophic scar measuring 5 mm in diameter. Other adverse effects were burning (PDL: 58%; ICG + DL: 68%), edema (PDL: 3%; ICG + DL: 10%), and purpura (PLD: 71%; ICG + DL, 42%).

Combination treatment

Two RCTs on laser treatment in combination with topical angiogenesis inhibitors were identified, and these trials had mixed findings. A 2013 RCT by Passeron et al included 22 children between the ages of 6 months and 18 years who had facial port wine stains no more than 100cm2.(5) Patients were randomized to receive PDL alone or laser followed by topical timolol. All patients received 3 laser sessions, with a month between sessions. For patients in the combination treatment group, timolol gel was applied twice daily beginning on the day of the first laser treatment and continuing until 15 days after the third and final treatment. Blinded evaluation of patients occurred at baseline and 1 month after the third laser session. In an intention-to-treat analysis, there was no statistically significant difference between groups in the clinical success rate of the 2 treatments, as measured by an investigator global assessment variable. This variable ranged from -1 (worsening) to 4 (complete clearance). A score of 3 (marked improvement) or 4 (complete clearance) was given to 1 of 10 patients treated with laser and 2 of 12 patients treated with combination therapy (p=1.0).

A 2012 study by Tremaine et al evaluated PDL treatment with and without the addition of imiquimod cream.(6) The study included 24 subjects with port wine stains. All patients initially received 1 session of laser treatment. Five patients enrolled in the study twice, with a washout period of at least 4 weeks before re-enrollment. Patients were randomized to receive additional treatment with either 5% imiquimod cream or placebo cream, to be applied 3 times a week for 8 weeks, beginning the day following laser treatment. Chromameter measurements were taken at baseline and at 8 weeks after laser treatment. The primary outcomes were change in erythema (defined as red/green color saturation with values ranging from +60 green to -60 red) and overall change in 3 color dimensions (reflected light intensity, green/red color saturation, and blue/yellow color saturation). The mean change (SD) in erythema was 0.43 (1.63) for the laser plus placebo sites and 1.27 (1.76) for the laser plus imiquimod sites. The difference between groups was statistically significant (p=0.03) and favored combined treatment. Similarly, the mean change (SD) in overall color was 2.59 (1.54) for laser plus placebo and 4.08 (3.39) for laser plus imiquimod (p=0.04).


Studies have generally found that laser treatment can be effective at lightening port wine stains. The preponderance of evidence is on the pulsed dye laser; there is insufficient evidence from comparative studies that 1 type of laser results in more lightening than another. There is insufficient evidence that adding topical angiogenesis inhibitor to laser therapy results in better outcomes than lasers alone. There was 1 positive RCT and 1 negative RCT. No comparative studies were identified on lasers combined with any other treatments. Thus, laser treatment may be considered medically necessary in certain situations for patients with port wine stains and combination treatment is considered investigational.

Practice Guidelines and Position Statements

No guidelines or statements were identified.

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.


  1. Faurschou A, Olesen AB, Leonardi-Bee J et al. Lasers or light sources for treating port-wine stains. Cochrane Database Syst Rev 2011; (11):CD007152.
  2. Faurschou A, Togsverd-Bo K, Zachariae C et al. Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation. Br J Dermatol 2009; 160(2):359-64.
  3. Babilas P, Schreml S, Eames T et al. Split-face comparison of intense pulsed light with short- and long-pulsed dye lasers for the treatment of port-wine stains. Lasers Surg Med 2010; 42(8):720-7.
  4. Klein A, Szeimies RM, Baumler W et al. Indocyanine green-augmented diode laser treatment of port-wine stains: clinical and histological evidence for a new treatment option from a randomized controlled trial. Br J Dermatol 2012; 167(2):333-42.
  5. Passeron T, Maza A, Fontas E et al. Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trial. Br J Dermatol 2013.
  6. Tremaine AM, Armstrong J, Huang YC et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol 2012; 66(4):634-41.





CPT  17106 - 17108 Destruction of cutaneous vascular proliferative lesions (e.g., laser technique) code range 
ICD-9 Procedure  86.3  Other local excision or destruction of lesion or tissue of skin and subcutaneous tissue (by and method) Note: No specific code to identify laser 
ICD-9 Diagnosis  757.32  Vascular hamartomas (port-wine stain) 
HCPCS  No code   
ICD-10-CM (effective 10/1/15) Q82.5 Congenital non-neoplastic nevus (includes port wine nevus)
ICD-10-PCS (effective 10/1/15) 0H50XZD, 0H50XZZ, 0H51XZD, 0H51XZZ, 0H54XZD, 0H54XZZ, 0H55XZD, 0H55XZZ, 0H56XZD, 0H56XZZ, 0H57XZD, 0H57XZZ, 0H58XZD, 0H58XZZ, 0H59XZD, 0H59XZZ, 0H5AXZD, 0H5AXZZ, 0H5BXZD, 0H5BXZZ, 0H5CXZD, 0H5CXZZ, 0H5DXZD, 0H5DXZZ, 0H5EXZD, 0H5EXZZ, 0H5FXZD, 0H5FXZZ, 0H5GXZD, 0H5GXZZ, 0H5HXZD, 0H5HXZZ, 0H5JXZD, 0H5JXZZ, 0H5KXZD, 0H5KXZZ, 0H5LXZD, 0H5LXZZ, 0H5MXZD, 0H5MXZZ, 0H5NXZD, 0H5NXZZ, Destruction, skin, external, single or multiple, code list [ICD-10-PCS would only be used if the procedure is done inpatient]
Type of Service  Surgery 
Place of Service  Outpatient 
Physician’s Office


Pulsed-dye laser treatment of port wine stains
Laser treatment of port wine stains
Port wine stain

Policy History

Date Action Reason
03/31/96 Add to Surgery section New policy
11/1/98 Replace policy Policy reviewed; policy statement revised
4/15/02 Replace policy Policy reviewed by consensus; new review date only
07/17/03 Replace policy Policy reviewed by consensus; policy unchanged; no further review scheduled
06/10/10 Replace policy Policy updated with literature search through April 2010; references 1-4 added. Policy changed to medically necessary and second policy statement on combined treatment added; condition in policy title changed to “port wine stains”.
6/9/11 Replace policy Policy updated with literature search through April 2011; references 3, 5-8 added. For clarity, “port wine stains” added to second policy statement.
06/14/12 Replace policy Policy updated with literature search through April 2012. References 1, 6 and 8 added. No change to policy statements.
6/13/13 Replace policy Policy updated with literature search through April 25, 2013. Reference 4 added; other references removed or renumbered.
6/12/14 Replace policy Policy updated with literature review through May 5, 2014. Reference 5 added. Policy statements unchanged


Resource Center

Find a Provider Find a Pharmacy Medicare Medicare Formulary